8 reports of this reaction
1.8% of all AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE reports
#13 most reported adverse reaction
SQUAMOUS CELL CARCINOMA is the #13 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, manufactured by Kenvue Brands LLC. There are 8 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE to SQUAMOUS CELL CARCINOMA. This represents approximately 1.8% of all 448 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE who experience squamous cell carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SQUAMOUS CELL CARCINOMA is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, but still significant enough to appear in the safety profile.
In addition to squamous cell carcinoma, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to squamous cell carcinoma in FDA adverse event reports:
SQUAMOUS CELL CARCINOMA has been reported as an adverse event in 8 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SQUAMOUS CELL CARCINOMA accounts for approximately 1.8% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, making it a notable side effect.
If you experience squamous cell carcinoma while taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.